L-鸟氨酸苯乙酸盐在急性肝损伤/肝衰竭伴高氨血症患者中的安全性、耐受性和药代动力学
47例急性肝损伤/肝衰竭且氨≥60 μM的患者接受L-鸟氨酸苯乙酸盐(OPA)剂量递增输注,最高20 g每24小时持续120小时;20 g组血浆苯乙酸达目标浓度,氨浓度曲线下面积较3.3或6.7 g组下降更明显,未发现与药物相关的严重不良事件。
要点
- OPA在急性肝损伤/肝衰竭患者中耐受良好,未发现安全性信号。
- 20 g每24小时输注可使血浆苯乙酸达目标浓度(<75 μg/mL为低于目标)。
- 20 g组氨浓度曲线下面积较3.3 g或6.7 g组下降更明显。
核心结论
- OPA在急性肝损伤/肝衰竭患者中耐受良好,未发现安全性信号。
- 20 g每24小时输注速率可达到目标血浆苯乙酸浓度,促使氨以苯乙酰谷氨酰胺形式经尿排泄,排泄量与肾功能成比例。
- 需要进行高剂量OPA的随机对照研究以确定其作为急性肝衰竭患者降氨剂的应用。
研究设计与样本
- 研究纳入47例急性肝损伤/肝衰竭且氨≥60 μM的患者。
- 患者接受OPA剂量递增方案,从3.3 g每24小时至10 g每24小时;15例患者在输注期间全程接受20 g每24小时,最长120小时。
主要发现
- 接受3.3 g每24小时的患者血浆苯乙酸浓度均低于目标(<75 μg/mL),中位数(四分位距)为5.0(5.0)μg/mL。
- 接受20 g每24小时的患者中,除1例外,其余患者血浆苯乙酸浓度均升至目标水平,中位数(四分位距)为150(100)μg/mL。
- 随着OPA剂量增加,血浆苯乙酰谷氨酰胺浓度升高,苯乙酸转化为苯乙酰谷氨酰胺的过程饱和。
- 尿苯乙酰谷氨酰胺清除率与肌酐清除率呈线性相关(r=0.831,P<0.0001)。
- 基于曲线下面积的氨平均浓度在20 g每24小时组较最大剂量3.3 g或6.7 g每24小时组下降更明显(P=0.046和P=0.022)。
关键数值与推荐
- 血浆苯乙酸目标浓度<75 μg/mL。
- 3.3 g每24小时组血浆苯乙酸中位数(四分位距)5.0(5.0)μg/mL。
- 20 g每24小时组血浆苯乙酸中位数(四分位距)150(100)μg/mL。
- 尿苯乙酰谷氨酰胺清除率与肌酐清除率线性相关(r=0.831,P<0.0001)。
- 20 g每24小时组氨浓度曲线下面积较3.3 g组(P=0.046)和6.7 g组(P=0.022)下降更明显。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需要进行高剂量OPA的随机对照研究以确定其作为急性肝衰竭患者降氨剂的应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Cerebral edema remains a significant cause of morbidity and mortality in patients with acute liver failure (ALF) and has been linked to elevated blood ammonia levels. l-ornithine phenylacetate (OPA) may decrease ammonia by promoting its renal excretion as phenylacetylglutamine (PAGN), decreasing the risk of cerebral edema. We evaluated the safety, tolerability, and pharmacokinetics of OPA in patients with ALF and acute liver injury (ALI), including those with renal failure. Forty-seven patients with ALI/ALF and ammonia ≥60 μM were enrolled. Patients received OPA in a dose escalation scheme from 3.3 g every 24 hours to 10 g every 24 hours; 15 patients received 20 g every 24 hours throughout the infusion for up to 120 hours. Plasma phenylacetate (PA) concentrations were uniformly below target (<75 μg/mL) in those receiving 3.3 g every 24 hours (median [interquartile range] 5.0 [5.0] μg/mL), and increased to target levels in all but one who received 20 g every 24 hours (150 [100] μg/mL). Plasma [PAGN] increased, and conversion of PA to PAGN became saturated, with increasing OPA dose. Urinary PAGN clearance and creatinine clearance were linearly related (r = 0.831, P < 0.0001). Mean ammonia concentrations based on the area under the curve decreased to a greater extent in patients who received 20 g of OPA every 24 hours compared with those who received the maximal dose of 3.3 or 6.7 g every 24 hours (P = 0.046 and 0.022, respectively). Of the reported serious adverse events (AEs), which included 11 deaths, none was attributable to study medication. The only nonserious AEs possibly related to study drug were headache and nausea/vomiting. CONCLUSION: OPA was well-tolerated in patients with ALI/ALF, and no safety signals were identified. Target [PA] was achieved at infusion rates of 20 g every 24 hours, leading to ammonia excretion in urine as PAGN in proportion to renal function. Randomized, controlled studies of high-dose OPA are needed to determine its use as an ammonia-scavenging agent in patients with ALF. (Hepatology 2018;67:1003-1013).
引用
- Stravitz RT, Gottfried M, Durkalski V, et al. Safety, tolerability, and pharmacokinetics of l-ornithine phenylacetate in patients with acute liver injury/failure and hyperammonemia. Hepatology. 2018. PMID: 29080224. doi:10.1002/hep.29621
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。